• Explore /
  • Poster
  • / Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

Abstract Poster

Authors

null

Bernard J. Escudier

Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France

Bernard J. Escudier , Robert J. Motzer , Padmanee Sharma , John Wagstaff , Elizabeth R. Plimack , Hans J. Hammers , Frede Donskov , Howard Gurney , Jeffrey Alan Sosman , Pawel Zalewski , Ulrika Harmenberg , David F. McDermott , Toni K. Choueiri , Martin Eduardo Richardet , Yoshihiko Tomita , Alain Ravaud , Justin Doan , Huanyu Zhao , Helene Hardy , Saby George

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01668784

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4509)

DOI

10.1200/JCO.2016.34.15_suppl.4509

Abstract #

4509

Poster Bd #

132

Abstract Disclosures

Similar Posters

First Author: Robert J. Motzer

First Author: Robert J. Motzer

First Author: Saby George

First Author: Ruchit Shah